Wells Fargo’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-6,000
| Closed | -$4K | – | 6830 |
|
|
2017
Q4 | $4K | Sell |
6,000
-200
| -3% | -$101 | ﹤0.01% | 6120 |
|
|
2017
Q3 | $2K | Sell |
6,200
-200
| -3% | -$70 | ﹤0.01% | 6196 |
|
|
2017
Q2 | $3K | Hold |
6,400
| – | – | ﹤0.01% | 6032 |
|
|
2017
Q1 | $8K | Buy |
6,400
+1,000
| +19% | +$1.25K | ﹤0.01% | 5954 |
|
|
2016
Q4 | $7K | Hold |
5,400
| – | – | ﹤0.01% | 5904 |
|
|
2016
Q3 | $11K | Hold |
5,400
| – | – | ﹤0.01% | 5750 |
|
|
2016
Q2 | $9K | Buy |
5,400
+99
| +2% | +$190 | ﹤0.01% | 5711 |
|
|
2016
Q1 | $5K | Sell |
5,301
-100
| -2% | -$98 | ﹤0.01% | 5890 |
|
|
2015
Q4 | $7K | Sell |
5,401
-4,200
| -44% | -$13.5K | ﹤0.01% | 5833 |
|
|
2015
Q3 | $71K | Buy |
9,601
+2,645
| +38% | +$20.2K | ﹤0.01% | 5113 |
|
|
2015
Q2 | $49K | Buy |
6,956
+2,723
| +64% | +$21.2K | ﹤0.01% | 5334 |
|
|
2015
Q1 | $37K | Buy |
4,233
+661
| +19% | +$5.91K | ﹤0.01% | 5138 |
|
|
2014
Q4 | $36K | Buy |
3,572
+1,258
| +54% | +$10.7K | ﹤0.01% | 5161 |
|
|
2014
Q3 | $23K | Buy |
2,314
+283
| +14% | +$4.19K | ﹤0.01% | 5248 |
|
|
2014
Q2 | $34K | Buy |
2,031
+1,444
| +246% | +$23.5K | ﹤0.01% | 5129 |
|
|
2014
Q1 | $10K | Buy |
587
+582
| +11,640% | +$11.3K | ﹤0.01% | 5416 |
|
|
2013
Q4 | $0 | Sell |
5
-3,173
| -100% | -$59.9K | ﹤0.01% | 6352 |
|
|
2013
Q3 | $85K | Buy |
3,178
+3,177
| +317,700% | +$68.1K | ﹤0.01% | 4525 |
|
|
2013
Q2 | $0 | Buy |
+1
| New | +$18 | ﹤0.01% | 5938 |
|
Wells Fargo's RPRX Position: Q1 2018 in Review
Wells Fargo sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 6,000 shares — an estimated $4K sold.
Wells Fargo first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $85K in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Wells Fargo reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Wells Fargo sold 6,000 Repros Therapeutics Inc. shares in Q1 2018, an estimated $4K.
- Wells Fargo first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Wells Fargo's Repros Therapeutics Inc. position peaked at $85K in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Wells Fargo's 13F filing for Q1 2018, filed 2 May 2018.